drug
metformin hydrochloride ER
Marketedupdated 3mo agoby Intellipharmaceutics Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval48 co-mentions · 22 sources
- drugSITAGLIPTIN AND METFORMIN HYDROCHLORIDE34 co-mentions · 26 sources
- drugmetformin33 co-mentions · 26 sources
- drugmetformin hydrochloride SR32 co-mentions · 26 sources
- drugmetformin hydrochloride32 co-mentions · 26 sources
- drugDAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE22 co-mentions · 10 sources
- drugDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE22 co-mentions · 10 sources
- drugDAPAGLIFLOZIN22 co-mentions · 10 sources
indications
investigational
Type 2 Diabetes
all catalysts(2)
Trials studying metformin hydrochloride ER
- phase1Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human
- phase1A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body
- phase1Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
- phase1A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
- phase1Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition
- phase1A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
- phase1Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
- phase4Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 24, 2026
98 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- May 1, 2035formulationUS 9962336
- Jan 21, 2029patentUS 8414921*PED2.4y
- Jan 21, 2029patentUS 8414921*PED2.4y
- Jul 21, 2028formulationUS 84149211.9y
- Jul 21, 2028formulationUS 84149211.9y
- May 24, 2027patentUS 7326708*PED279d
- May 24, 2027patentUS 7326708*PED279d
- Nov 24, 2026compositionUS 732670898d
- Nov 24, 2026compositionUS 732670898d
- Jul 31, 2026formulationUS 7785627
- Jul 31, 2026formulationUS 7785627
- Jul 31, 2026formulationUS 7959946
- Jul 31, 2026formulationUS 7959946
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that